Growth Hormone + Insulin Resistance: Why Timing Matters

Why Growth Hormone and Food Together Can Make You Insulin Resistant

Growth hormone does something very specific when it hits your system, and to understand why timing matters you have to follow the whole chain from injection to what your muscle cells actually burn.

Growth hormone tells your fat cells to release stored fat into your bloodstream. That fat travels as free fatty acids, and the point of releasing it is so your body has something to burn. Adipose tissue works as an active endocrine organ that shifts what it releases based on the signals it gets, and where that fat sits on your body changes how it behaves metabolically (Camastra and Ferrannini, 2022).

Then food enters the picture, and the whole chain of events gets more complicated.

You eat, glucose enters your blood, your pancreas releases insulin, and insulin's job is to knock on the door of your muscle cell and get that glucose inside. And this is exactly why people say growth hormone creates insulin sensitivity because the presence of insulin indicates that you have glucose in your blood and that transports that sugar to your muscles so they can use it as a source of fuel.

Up to this point the system is doing exactly what it is supposed to do, with fat and sugar each moving toward the cells that need them.

Well, when we have fat present in our blood, aka the fat that was created from the growth hormone to be used as a source of energy, plus we have sugar, it's creating a competition in your body for which resource to use as fuel.

Your muscle cell can only run one fuel at a time in any meaningful volume. When fatty acid oxidation is already running, the byproducts build up inside the cell and start shutting down the enzymes that handle glucose. Long-chain acyl CoA esters accumulating inside muscle are one of the clearest links between fat availability and blunted glucose uptake (Cooney et al., 2002).

Researchers gave this exact competition a label decades ago. It is called the Randle cycle, or the glucose fatty acid cycle, which describes how fat and sugar suppress each other's use inside the same cell. In people with type 2 diabetes, raising circulating free fatty acids measurably lowers glucose oxidation and glucose uptake, which is the Randle cycle running in a live human being (Bevilacqua et al., 1990).

This additional competition means that that insulin is now competing, it's creating insulin resistance just by being present at the same time.

Think of it like a loading dock with one door. Fat showed up first and is already unloading, so when the glucose truck pulls in, insulin is standing there knocking and nothing opens. Your pancreas reads that as "not enough insulin" and sends more, so blood sugar stays elevated longer than it should even though nothing has actually failed.

Your insulin receptors are working fine the whole time, since the door itself simply has a truck already parked in it.

Timing the injection around meals fixes most of this. Take your growth hormone when there is no food competing with it, which for most people means first thing in the morning before eating, or several hours after the last meal before bed. You are giving the fat a window where it is the only fuel in the system, so it gets burned instead of sitting in circulation gumming up glucose handling.

I cannot point you to a study that directly compares fasted versus fed growth hormone administration and measures insulin resistance as the outcome, so treat the timing advice as mechanism plus what I see with clients rather than something the literature has settled. Researchers have documented the Randle cycle thoroughly across decades of metabolic studies. The specific dosing protocol built on top of it is inference.

Research: Bevilacqua et al., Diabetes, 1990; Camastra and Ferrannini, Rev Endocr Metab Disord, 2022; Cooney et al., Ann N Y Acad Sci, 2002.

References:

Bevilacqua S, Buzzigoli G, Bonadonna R et al.. Operation of Randle's cycle in patients with NIDDM. Diabetes. 1990. https://pubmed.ncbi.nlm.nih.gov/2307295/

Camastra S, Ferrannini E. Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review. Rev Endocr Metab Disord. 2022. https://pubmed.ncbi.nlm.nih.gov/35031911/

Cooney GJ, Thompson AL, Furler SM et al.. Muscle long-chain acyl CoA esters and insulin resistance. Ann N Y Acad Sci. 2002. https://pubmed.ncbi.nlm.nih.gov/12079848/